scholarly journals SERS Based Lateral Flow Immunoassay for Point-of-Care Detection of SARS-CoV-2 in Clinical Samples

2021 ◽  
Vol 4 (4) ◽  
pp. 2974-2995 ◽  
Author(s):  
Shalu Yadav ◽  
Mohd. Abubakar Sadique ◽  
Pushpesh Ranjan ◽  
Neeraj Kumar ◽  
Ayushi Singhal ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Clinical Samples ◽  
Point Of Care Detection

scholarly journals Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Liding Zhang ◽  
Xuewei Du ◽  
Ying Su ◽  
Shiqi Niu ◽  
Yanqing Li ◽  
...  
Keyword(s):  
Point Of Care ◽  
Elisa Test ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Csf Biomarkers ◽  
Transient Nature ◽  
Prodromal Alzheimer’S Disease ◽  
Csf Levels ◽  
Point Of Care Detection

AbstractAβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract

An enhanced centrifugation-assisted lateral flow immunoassay for the point-of-care detection of protein biomarkers

Lab on a Chip ◽  
2020 ◽  
Vol 20 (15) ◽  
pp. 2626-2634 ◽  
Author(s):  
Minjie Shen ◽  
Nan Li ◽  
Ying Lu ◽  
Jing Cheng ◽  
Youchun Xu
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Protein Biomarkers ◽  
Protein Biomarker ◽  
Blood Samples ◽  
Point Of Care Detection

An enhanced centrifugation-assisted lateral flow immunoassay was proposed for automated protein biomarker detections using blood samples within 15 minutes.

Upconversion nanoparticles-based lateral flow immunoassay for point-of-care diagnosis of periodontitis

2021 ◽  
Vol 334 ◽  
pp. 129673
Author(s):  
Wanghong He ◽  
Minli You ◽  
Zedong Li ◽  
Lei Cao ◽  
Feng Xu ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Upconversion Nanoparticles

scholarly journals Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis

2020 ◽  
Vol 58 (9) ◽  
Author(s):  
Katharina Ziegler ◽  
Anca Rath ◽  
Christoph Schoerner ◽  
Renate Meyer ◽  
Thomas Bertsch ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Roc Curve ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lyme Neuroborreliosis ◽  
Diagnostic Tools ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
European Federation ◽  
Point Of Care Test

ABSTRACT Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia-specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA. Classification of patients followed the European Federation of Neurological Societies (EFNS) guidelines on LNB. The CXCL13 ELISA detected elevated CXCL13 levels in all patients with definite LNB (median, 1,409 pg/ml) compared to the non-LNB controls (median, 20.7 pg/ml; P < 0.0001), with a sensitivity of 100% and a specificity of 84.8% (cutoff value, 78.6 pg/ml; area under the receiver operating characteristic [ROC] curve, 0.93). Similarly, the CXCL13 LFA yielded elevated CXCL13 levels in 31 patients with definite LNB (median arbitrary value, 223.5) compared to the non-LNB control patients (median arbitrary value, 0; P < 0.0001) and had a sensitivity and specificity of 91.2% and 93.5%, respectively (cutoff arbitrary value, 22.5; area under the ROC curve, 0.94). The correlation between the CXCL13 levels obtained by ELISA and LFA was strong (Spearman correlation coefficient r = 0.89; P < 0.0001). The CXCL13 ELISA and the CXCL13 LFA are comparable diagnostic tools for the detection of CXCL13 in the CSF of patients with definite LNB. The advantage of the CXCL13 LFA is the shorter time to result.

Lateral Flow Assay Based on Paper-Hydrogel Hybrid Material for Sensitive Point-of-Care Detection of Dengue Virus

2016 ◽  
Vol 6 (1) ◽  
pp. 1600920 ◽  
Author(s):  
Jane Ru Choi ◽  
Kar Wey Yong ◽  
Ruihua Tang ◽  
Yan Gong ◽  
Ting Wen ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Hybrid Material ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Point Of Care Detection
Sign in / Sign up

Export Citation Format

Share Document